INTRODUCTION: Presence of circulating DNA in the serum of patients with cancer makes detection of tumour-specific genetic alterations feasible. OBJECTIVE: To study serum DNA concentration in patients diagnosed as having advanced Non-Small Cell Lung Cancer (NSCLC) and to evaluate its relationship with age, histology, stage, response, time-to-progression (TTP), and survival. METHODS: Serum DNA from 78 patients was purified and spectrophotometrically quantified. RESULTS: No significant correlations were found between serum DNA concentration and age, histology, response and survival. There was a significant correlation with respect to stage (IIIB = 408.75 ng/ml; IV = 478.74 ng/ml; p = 0.02). When patients were grouped according to DNA concentration, significant correlation with TTP was found; establishing a cut-off point at 500 ng/ml ([DNA] < 500 ng/ml TTP = 7.25 months, 95%CI: 3.5-5.25; [DNA ] > or = 500 ng/ml TTP = 4.25 months, 95%CI: 2-6.5; p = 0.05). CONCLUSIONS: Using the present method, DNA concentration quantification appears to be simple, but with certain deficiencies due to inter-sample variability and low specificity. This is because total DNA concentration is measured without distinguishing as to whether it is tumour-related. We suggest that there is a correlation between DNA concentration and prognosis which enables an analysis of the natural history of the disease.
INTRODUCTION: Presence of circulating DNA in the serum of patients with cancer makes detection of tumour-specific genetic alterations feasible. OBJECTIVE: To study serum DNA concentration in patients diagnosed as having advanced Non-Small Cell Lung Cancer (NSCLC) and to evaluate its relationship with age, histology, stage, response, time-to-progression (TTP), and survival. METHODS: Serum DNA from 78 patients was purified and spectrophotometrically quantified. RESULTS: No significant correlations were found between serum DNA concentration and age, histology, response and survival. There was a significant correlation with respect to stage (IIIB = 408.75 ng/ml; IV = 478.74 ng/ml; p = 0.02). When patients were grouped according to DNA concentration, significant correlation with TTP was found; establishing a cut-off point at 500 ng/ml ([DNA] < 500 ng/ml TTP = 7.25 months, 95%CI: 3.5-5.25; [DNA ] > or = 500 ng/ml TTP = 4.25 months, 95%CI: 2-6.5; p = 0.05). CONCLUSIONS: Using the present method, DNA concentration quantification appears to be simple, but with certain deficiencies due to inter-sample variability and low specificity. This is because total DNA concentration is measured without distinguishing as to whether it is tumour-related. We suggest that there is a correlation between DNA concentration and prognosis which enables an analysis of the natural history of the disease.
Authors: G Sozzi; D Conte; L Mariani; S Lo Vullo; L Roz; C Lombardo; M A Pierotti; L Tavecchio Journal: Cancer Res Date: 2001-06-15 Impact factor: 12.701
Authors: Jose M Silva; Javier Silva; Antonio Sanchez; Jose M Garcia; Gemma Dominguez; Mariano Provencio; Luis Sanfrutos; Eugenia Jareño; Antonio Colas; Pilar España; Felix Bonilla Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: X Chen; H Bonnefoi; S Diebold-Berger; J Lyautey; C Lederrey; E Faltin-Traub; M Stroun; P Anker Journal: Clin Cancer Res Date: 1999-09 Impact factor: 12.531
Authors: F Coulet; H Blons; A Cabelguenne; T Lecomte; O Lacourreye; D Brasnu; P Beaune; J Zucman; P Laurent-Puig Journal: Cancer Res Date: 2000-02-01 Impact factor: 12.701
Authors: J B de Kok; W W van Solinge; T J Ruers; R W Roelofs; G N van Muijen; J L Willems; D W Swinkels Journal: Scand J Clin Lab Invest Date: 1997-11 Impact factor: 1.713
Authors: J L Ramirez; M Taron; C Balaña; C Sarries; P Mendez; I de Aguirre; L Nuñez; B Roig; C Queralt; M Botia; R Rosell Journal: Rocz Akad Med Bialymst Date: 2003
Authors: Brant G Wang; Han-Yao Huang; Yu-Chi Chen; Robert E Bristow; Keyanunoosh Kassauei; Chih-Chien Cheng; Richard Roden; Lori J Sokoll; Daniel W Chan; Ie-Ming Shih Journal: Cancer Res Date: 2003-07-15 Impact factor: 12.701